Serum lactic dehydrogenase (LDH) is an important prognostic factor in patients with non-Hodgkin's lymphoma (NHL). We have examined the LDH isoenzyme content in serum and CSF of patients with NHL, at diagnosis and at relapse. In patients with increased serum LDH at diagnosis, the percentage of isoenzyme 2 was increased in 52% of patients and the absolute value of isoenzyme 3 was increased in 64% of patients. In relapsing patients these values were respectively 69% and 65%. Conversely in patients with increased serum LDH due to myeloid regeneration after chemotherapy, isoenzymes 4 and 5, but not isoenzymes 2 or 3, were increased. High absolute values of isoenzyme 3 were correlated with an altered performance status, advanced tumor stage, and agressive histology whereas high isoenzyme 2 percentages were correlated with altered performance status only. Among patients with high total serum LDH, a high content of isoenzyme 2 and a high absolute value of isoenzyme 3 were correlated with high serum levels of TNF␣ and TNF receptor p75. Analysis of total LDH and LDH isoenzyme profiles in CSF did not reveal any correlation with meningeal involvement by lymphoma. High isoenzyme 2 percentages and high absolute values of isoenzyme 3 in serum were both significantly associated with a shorter freedom-fromprogression and overall survival. Isoenzyme 3 remained a prognostic factor for survival even when considering only patients with high total serum LDH at diagnosis. We conclude that there are some characteristic serum LDH isoenzyme profiles in patients with NHL and that some of these specific alterations may help refine the prognostic value of total serum LDH.
Introduction
Serum lactic dehydrogenase (LDH) is one of the components of the International Prognostic Index, which is a strong predictor of survival in patients with non-Hodgkin's lymphoma (NHL). 1 LDH above normal values carry a poor prognosis and very high values are even worse. 2 Other biological predictors of outcome include serum ␤2 microglobulin, serum TNF␣ and TNF receptors, and certain characteristics of tumor cells, such as altered expression of p53. [3] [4] [5] Lactic dehydrogenase catalyses the reversible transformation between pyruvate and lactate. LDH is a tetramer composed of two types of monomers, H (for 'heart', also designated as 'B'), and M (for 'muscle', also designated as 'A'). 6 There are five isoenzymes corresponding to the various combinations of these monomers: isoenzyme 1 (B4), isoenzyme 2 (AB3), isoenzyme 3 (A2B2), isoenzyme 4 (A3B) and isoenzyme 5 (A4). The forms with a high B content are found in tissues with a steady oxygen supply (heart, brain), whereas tissues which produce large amounts of lactic acid, such as Some LDH isoenzymes have been shown to be specifically modified in various neoplastic diseases such as breast cancer, CNS tumors, ovarian cancer and testicular tumors. [8] [9] [10] [11] Serum LDH isoenzymes have also been analyzed in hematological malignancies. Increased isoenzyme 3 content has been reported in patients with multiple myeloma, and chronic granulocytic leukemia.
12, 13 Patel et al 14 have reported that the increase in LDH isoenzyme 2 values was observed in 84% of patients with untreated leukemia. Csako et al 15 described a series of nine patients with Burkitt's lymphoma and high serum LDH at diagnosis. These patients displayed an increase of their absolute serum values of LDH isoenzymes 2 and 3, and an increase in the percentage of isoenzyme 3.
In this report, we describe the LDH isoenzyme profiles in the serum of NHL patients at diagnosis or at relapse, and in the cerebrospinal fluid (CSF) of NHL patients with or without meningeal involvement by lymphoma cells. These results were compared to the isoenzyme profiles observed in patients with high serum LDH due to myeloid regeneration. We also determined the presence of isoenzyme alterations according to some known prognostic factors, such as stage, performance status (PS), and serum tumor necrosis factor (TNF) and TNF receptor values.
Patients and methods

Samples
Serum samples were drawn from 172 patients (130 at diagnosis and 42 at relapse) with NHL at the Department of Hematology in the Centre Hospitalier Lyon Sud between January 1996 and December 1997. Characteristics of patients at diagnosis are shown in Table 1 . Among the 130 patients studied at diagnosis, the median age was 59 years (range 17-84), 63 had agressive lymphoma (diffuse large cell, Burkitt, lymphoblastic, or histological transformation), 30 had a PS у2 and 72
Figure 1
Serum LDH isoenzyme percentages in controls and NHL patients at diagnosis depending on total serum LDH. Median values are indicated by the lines in the boxes. Boxes indicate standard errors and lines indicate the range.
had disseminated disease (stages III and IV). None of these patients had an obvious reason to have increased LDH when serum was drawn (hemolysis in sample, pulmonary embolism, myocardial infarction, post-surgical period). Samples were also obtained from 42 patients with relapsing NHL and from 19 patients who had temporarily increased total serum LDH during myeloid regeneration after chemotherapy. Forty-three CSF samples were drawn by lumbar puncture during diagnostic workup or before administering intrathecal methotrexate.
Assay of enzyme activity and isoenzyme profiles
Total LDH activity was determined by a routinely used spectrophotometric method (Boehringer Kit, Meylan, France) in a discrete analyzer (Hitachi 917; Boehringer). The extinction was automatically recorded at 340 nm. LDH isoenzymes were separated by agarose gel electrophoresis (Titan gel LD-kit isoenzyme procedure; Helena Laboratories, Beaumont, TX, USA). Lactate was used as the substrate to detect enzyme
Figure 2
Serum LDH isoenzyme percentages in controls and in NHL patients with increased total serum LDH in different situations. This figure compares the isoenzyme profiles in controls, NHL patients at diagnosis, NHL patients at relapse, and in patients with increased total serum LDH due to myeloid regeneration after chemotherapy. Results shown are median values + s.e. activity. LDH isoenzymes were visualized by nitroblue tetrazolium reduction to formazan. The gels were scanned with an integrated densitometer (Cellosystem 2; Sebia, Issy-lès-Moulineaux, France) for determination of the different LDH isoenzyme activities.
TNF␣ and TNF receptor assays
Samples were available from 49 patients. Blood was drawn in tubes containing EDTA to prevent further cytokine release from circulating mononuclear cells before analysis. Plasma samples were tested with enzyme-linked immunoadsorbent assay kits for TNF␣ (Medgenix Diagnostic, Fleurus, Belgium), and p55 and p75 (Roche, Basel, Switzerland). The detection limits were 3 pg/ml for TNF, 0.1 ng/ml for p55 and 1 ng/ml for p75.
Statistical analysis
Comparison of isoenzyme 2 contents according to performance status, stage distribution, indolent vs aggressive histology, and increased vs normal total serum LDH were performed using a non-parametric 2 test. Overall survival (OS) was defined as the interval between diagnosis and death or loss to follow-up. Freedom-from-progression survival (FFP) was defined as the interval between diagnosis and progression. Survival was analyzed according to the method of Kaplan and Meier and differences between survival curves were evaluated with the log-rank test. Statistical analyses were performed using Statistica software.
Results
Serum isoenzyme profiles in NHL patients
Among the 130 patients with NHL at diagnosis, 58 patients (45%) and 26 of the 42 relapsing patients (62%) had increased serum LDH. The isoenzyme percentages of the patients according to total serum LDH level are shown in Figure 1 . Isoenzyme 2 percentages were significantly higher in patients with increased vs normal total serum LDH (P Ͻ 0.0001). Absolute values of isoenzymes 1, 2, 3, 4 and 5 were increased in 58%, 86%, 64%, 50% and 36% of patients with high total serum LDH at diagnosis. In patients with increased total serum LDH, LDH isoenzyme 2 percentages were increased in 52% of the patients (70% when total LDH was greater than twice the normal value) whereas other isoenzyme percentages were infrequently increased (10% for isoenzyme 1, 3% for isoenzyme 3, 14% for isoenzyme 4, 9% for isoenzyme 5). In 26 relapsing patients with high serum LDH values, 18 (69%) had increased serum isoenzyme 2 percentages and 65% had increased absolute values of isoenzyme 3. In NHL patients with normal total serum LDH at diagnosis, 18% had increased isoenzyme 2 percentages and only 1/72 patients had an increased value of isoenzyme 3. In NHL patients with increased total serum LDH, increased absolute isoenzyme 2 values thus appear to be the most frequent, and increased absolute values of isoenzyme 3 are the most specific abnormalities.
Serum LDH isoenzymes during myeloid regeneration
Serum LDH profiles were analyzed in 19 patients who had increased total serum LDH due to myeloid regeneration after chemotherapy. These patients did not have any other obvious cause of increased serum LDH and had normal LDH values before their aplasia. As shown in Figure 2 , isoenzymes 4 and 5, rather than isoenzyme 2, were increased in this situation.
CSF LDH isoenzymes in NHL patients
CSF was drawn from 43 patients with NHL in whom lumbar puncture was performed for intrathecal administration of Values shown indicate the number of patients in each group. % iso2: percentage of isoenzyme 2 in total serum LDH; iso3: absolute values of isoenzyme 3 LDH in serum. (Figure 3) .
Correlation of isoenzymes with other prognostic factors
As shown in Table 2 , isoenzyme 3 values were found to be more frequently increased in patients with poor performance status (ECOG у2, disseminated disease or with agressive disease. Isoenzyme 2 percentages were more frequently increased in patients with patients with poor performance status. Among the 58 patients with increased total serum LDH at diagnosis, isoenzyme 2 content was increased in 70% (14 out of 20 patients) of the patients with a performance status of 2 or more, and in 42% (16 out of 38 patients) of the patients with a performance status of 0 or 1.
TNF values in NHL patients
Median serum TNF␣ and TNF receptor contents were found to be increased in NHL patients at diagnosis, as we have previously reported (Table 3) . Serum TNF and p75 receptor values were increased in patients with high total serum LDH or high serum LDH isoenzyme 2 percentages and were particularly increased in patients who displayed both of these alterations. Similar results were found in patients with high isoenzyme 3 values (data not shown), except for the fact that in this sample of 49 patients none of the patients with normal total serum LDH had elevated isoenzyme 3 values.
Prognostic value of serum LDH isoenzymes
Increased isoenzyme 2 percentages were significantly associated with shorter overall survival (P = 0.03, Figure 4 ) and shorter FFP (P = 0.05, data not shown). In patients with high total serum LDH, high isoenzyme 2 was not significantly associated with worse OS or FFP (P = 0.10, data not shown) but this may be due to the small size of the patient sample. Conversely, high isoenzyme 3 values were correlated both with shorter OS (P Ͻ 0.0001, Figure 5 ) and FFP (P = 0.005, data not shown), even in patients with high total serum LDH (OS: P = 0.002, Figure 6 ; FFP: P = 0.04, data not shown). In this small patient sample increased total serum LDH was associated with shorter OS (P = 0.001) but not with shorter FFP (P = 0.18) (data not shown).
Discussion
Increased serum LDH is a common finding in patients with cancer and is generally attributed to tumor agressiveness or a high tumor burden. High total serum LDH carry a poor prognosis in myeloma, childhood ALL, melanoma, lung adenocarcinoma and colorectal carcinom. [16] [17] [18] [19] [20] Many authors have shown that high serum LDH is a major prognostic factor in patients with NHL. Total serum LDH is one of the parameters
Figure 4
Overall survival in NHL patients according to the isoenzyme 2 percentage of total serum LDH at diagnosis. Dotted line: patients with normal isoenzyme 2 percentages; solid line: patients with high isoenzyme 2 percentages.
Figure 5
Overall survival in NHL patients according to the LDH isoenzyme 3 serum values at diagnosis. Dotted line: patients with normal isoenzyme 3 values; solid line: patients with high isoenzyme 3 values.
of the International Prognostic Index used in patients with NHL. 1 Although LDH is routinely measured in patients with NHL at diagnosis, there are very little data regarding the isoenzyme content of LDH in these patients. Isoenzyme 3 has been reported to be the most abundant isoenzyme in normal lymphoid tissue. It is remarkable that single doses of steroids have been shown to modify the LDH isoenzyme patterns of LDH in lymphocytes in vivo. Ten Berge et al 21 showed a significant decrease of the H/M ratio in T lymphocytes after a single oral administration of prednisolone. Plum et al 22 reported a low B:A ratio in the LDH tetramers in T␥ lymphocytes.
Our main finding is that there are characteristic isoenzyme profiles in NHL patients with increased total serum LDH at diagnosis and these alterations have a prognostic value. Both an increase in the percentage of isoenzyme 2 and an increase in the absolute values of isoenzyme 3 were found to predict shorter overall survival and freedom-from-progression survival. Isoenzyme 3 maintained its prognostic value even when only patients with increased total serum LDH were considered. Isoenzyme 3 being the most abundant form in lymphoid tissues, it is possible that increased values of serum isoenzyme 3 directly reflect the tumor mass in patients with NHL. It remains to be determined whether increased isoenzyme 2 is released by the tumor itself or whether it is produced by the host in response to the disease. Analysis of isoenzyme contents in tumor samples should provide insight as to the origin of increased isoenzymes 2 and 3 in serum.
Altered isoenzyme profiles in CSF have been suggested to be diagnostic of leptomeningeal malignancy. 23 Our results show neither a significant increase of total LDH in CSF nor an alteration in the LDH isoenzyme profile, in patients with meningeal involvement by lymphoma cells. The data suggest that LDH and LDH isoenzymes in CSF cannot be used as markers of meningeal involvement in patients with NHL.
Figure 6
Overall survival in NHL patients with increased total serum LDH at diagnosis according to the LDH isoenzyme 3 serum values. Dotted line: patients with normal isoenzyme 3 values; solid line: patients with high isoenzyme 3 values.
Regulation of LDH subunits is multifactorial. Hypoxia, protein kinases, various hormones and growth factors have been shown to regulate LDH gene expression. [24] [25] [26] In most cases, these factors induce a shift towards A-subunit containing isoenzymes which can derive more energy under anaerobic conditions. More recently it has been shown that TNF␣ is capable of inducing LDH-A expression in cultured Sertoli cells. 27 Human lymphoma cells obtained from fresh tumor samples have been shown to produce TNF. 28 Our results show that patients with high serum isoenzyme 2 content have higher serum concentrations of TNF␣ and p75 receptor. The latter have been reported to be independent prognostic factors of survival in patients with NHL. 4 It is therefore possible that the serum LDH isoenzyme alterations observed in NHL patients may be due, among other factors, to the production of inflammatory cytokines such as TNF.
Increased serum LDH is observed in a number of non-neoplastic diseases. Increased isoenzyme 1 (1/2 'flip') is observed in myocardial and renal infarctions. Increased isoenzyme 5 is observed in muscular necrosis, in cases of liver damage and in mononucleosis. Pulmonary embolism causes increases in isoenzymes 2 and 3. Increased serum LDH is not a specific marker of neoplasia, but can be quite useful to determine prognosis or to follow therapeutic efficacy. Insofar as the isoenzyme 2 content appears to be selectively increased in some patients with NHL and this increase is associated with high serum TNF values, LDH isoenzyme profiles may help to refine the prognostic value of total serum LDH in NHL patients at diagnosis.
